Abstract
Introduction
Overall approximately 3 million women in the US are living with breast cancer.
But, even with an increasing incidence, the mortality rate has dropped
slightly during the last 10-15 years. The most dramatic decrease is seen in
younger patients (<50 years). In the past decade the regulatory authorities
in US have approved five hormone-based therapies (Faslodex, Femara, Aromasin,
Nolvadex and Arimidex), two chemotherapies (Xeloda and Taxotere) and one
monoclonal antibody (Herceptin) as a treatment option for breast cancer.
AstraZeneca reported increased sales of Arimidex during 2005 up 38% to $1.2
billion. Faslodex increased (+39%) to $140 million whereas Nolvadex decreased
(-16%) to $114 million. Novartis reported that Femara increased it sell value
by +30% to $326 million for the first 6 months in 2006. Net U.S. sales of
Herceptin increased 56% to $747.2 million in 2005 and 18% to $479.0 million
during 2004. According to UK estimates, the switching of 100 000 women from
tamoxifen to Arimidex will cost nearly 100 million.
Research and analysis highlights
In the report "Breast Cancer - A Therapeutic & Competitive Insight" BioSeeker
does not only describe and analyze the latest years of progress but as well
provide an insight and framework to understand the complex field of breast
cancer therapeutics. In this report, we provide one of the most comprehensive
coverage of the R&D trends to set the future marketplace. BioSeeker presents
both an overview and a detailed description on the progress of key drugs in
Phase III and II development, together with general descriptions on drugs and
targets. We have identified 170 drug candidates in clinical stage of
development and more than 100 companies are involved in the development of
these drugs. Among these drugs we clearly see substantial progress while
others have failed. There will be a more intense competition in this market
and current treatments will be changed for the benefit of more innovative
therapies. Hormone modifying therapies together with different
chemotherapeutic schedules have been of highest intrest during the last years
of progress. A vast amount of new clinical research data has emerged and
several new clinical trials have been iniated and others generated new
results. Protein kinase inhibitors and epothilones have generated substantial
amount of new research data in this field. But, other strategies seem not
successful and we are still waiting new information regarding their progress.
Scope of this report
- Thorough examination of status and impact of several novel drugs in
development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
Key reasons to read this report
- Explore the strengths and weaknesses associated with compounds in clinical
development.
- Scientific rationale for most novel therapeutics in breast cancer R&D, and
the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities
associated with breast cancer therapy
- One hundred high quality references
| 
View Cart
